DSS1(V) Antibody

What is DSS1(V) and how does it differ from DSS1(I)?

DSS1(V) is a variant form of the DSS1 (Deleted in Split hand/Split foot 1) protein. While both DSS1 types share similar binding energies with BRCA2B and non-ATPase subunit 9 (ATS9), they exhibit distinct partner preferences. DSS1(V) specifically binds to enhanced ethylene response 5 protein (EERH5, AT2G19560), whereas DSS1(I) preferentially interacts with the AAA-type ATPase family protein (AT5G2000) . These binding differences reflect subtle but significant structural variations between the two forms that influence their biological functions and interaction networks.

Why are DSS1 proteins difficult to detect using antibodies in Western blots?

Multiple studies have documented difficulties in detecting DSS1 protein on Western blots using antibodies . This challenge likely stems from several factors:

• Low abundance of endogenous DSS1 protein

• Small size (approximately 70 amino acids) providing limited epitopes

• Potential sequestration within hydrophobic pockets of binding partners

For reliable detection, researchers often employ alternative approaches such as:

• Epitope tagging strategies (e.g., Flag or HA tags)

• Enhanced immunoprecipitation protocols

• RT-PCR for mRNA level analysis when protein detection proves difficult

What are the recommended protocols for immunofluorescence detection of DSS1?

For successful immunofluorescence detection of DSS1:

• Fix cells with 4% paraformaldehyde for 10 minutes

• Permeabilize with 0.5% Triton X-100 for 10 minutes

• Block with 4% bovine serum albumin in PBS for 30 minutes

• Incubate with primary antibody overnight at 4°C

• Wash three times with PBS

• Apply secondary antibody for 1 hour at room temperature

• Mount with ProLong Gold Antifade Mountant with DAPI

For quantification, use confocal microscopy with software like Fiji/ImageJ2 to distinguish nuclear and cytoplasmic signals. This protocol has successfully demonstrated nuclear localization of DSS1 .

How can researchers validate DSS1(V) antibody specificity when commercial options show cross-reactivity?

Validating antibody specificity for DSS1(V) requires a multi-layered approach:

• CRISPR/Cas9 knockout validation: Generate DSS1(V)-specific knockout cell lines using targeted disruption approaches. Antibody signals should disappear in these knockout lines while remaining in wildtype cells.

• Peptide competition assay: Pre-incubate the antibody with synthetic peptides representing unique regions of DSS1(V) versus DSS1(I). A specific antibody will show diminished signal only when pre-incubated with the DSS1(V) peptide.

• Overexpression controls: Compare antibody reactivity in systems overexpressing tagged DSS1(V) versus DSS1(I). Use both western blotting and immunofluorescence to confirm specificity.

• Western blot validation: Effective antibodies should detect a band at the expected molecular weight that disappears upon targeted degradation methods (e.g., dTAG system treatment as demonstrated for DSS1) .

What experimental approaches can distinguish the functional roles of DSS1(V) compared to DSS1(I) in DNA repair pathways?

To distinguish the functional roles of DSS1 variants in DNA repair:

• Selective binding partner disruption: Utilize the W39R mutation strategy demonstrated for DSS1, which disrupts interaction with INTAC without affecting proteasome binding . Create equivalent selective binding mutations for DSS1(V).

• RAD51 focus formation assay: Selectively silence DSS1(V) versus DSS1(I) and quantify the impact on RAD51 focus formation after DNA damage . Differences would indicate variant-specific roles in homologous recombination.

• Complementation experiments: In cells with endogenous DSS1 depletion, introduce either DSS1(V) or DSS1(I) and measure restoration of:

  • Clonogenic capacity

  • DNA damage repair efficiency

  • Protein stability of known DSS1-dependent substrates

• ChIP-seq comparative analysis: Compare chromatin associations of DSS1(V) versus DSS1(I) to identify variant-specific genomic targets.

What methodological adjustments are necessary when using DSS1(V) antibodies for CUT&Tag experiments?

When performing CUT&Tag experiments with DSS1(V) antibodies:

• Sample preparation optimization: Given that DSS1 has been shown to be sequestered within hydrophobic pockets of binding partners , standard crosslinking approaches may obscure antibody recognition. Use the modified CUT&Tag protocol established for DSS1:

  • Employ gentler cell permeabilization with digitonin

  • Increase antibody incubation time (overnight at 4°C)

  • Include secondary antibody amplification steps with rabbit anti-mouse IgG and mouse anti-rabbit IgG

• Tagmentation conditions:

  • Prepare pAG-Tn5 adapter complex in dig-300 buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM spermidine, protease inhibitors, 0.01% digitonin, 0.01% NP-40)

  • Perform tagmentation at 37°C for 1 hour in tagmentation buffer (10 mM TAPS-KOH pH 8.3, 10 mM MgCl2, 1% DMF)

• Controls: Include both IgG controls and dTAG-mediated depletion samples (if using tagged DSS1 systems) to establish signal specificity .

How do researchers map the critical residues for DSS1(V) interactions with its binding partners?

To map critical interaction residues:

• Structural analysis approach: Following the example of DSS1-INTS7 interaction analysis , use computational structural analysis to identify potential interface residues, particularly focusing on hydrophobic interactions.

• Mutational strategy: Generate site-directed mutants at predicted interface residues. The W39R mutation in DSS1 provides an excellent model - this substitution of tryptophan with a positively charged arginine disrupted INTAC interaction without affecting proteasome binding .

• Validation through co-immunoprecipitation: Express mutant forms of DSS1(V) with epitope tags and quantify their interaction with binding partners compared to wild-type DSS1(V).

• Functional rescue experiments: Test whether mutant forms can rescue phenotypes associated with DSS1(V) depletion.

What are the recommended controls when studying DSS1(V) degradation kinetics?

When studying DSS1(V) degradation kinetics:

• Endogenous tag systems: Utilize CRISPR/Cas9-mediated endogenous tagging strategies, such as the dTAG system demonstrated for DSS1 . This allows for controlled degradation of the endogenous protein.

• Cycloheximide chase experiments: Include cycloheximide (CHX) treatment to inhibit protein synthesis, allowing accurate measurement of protein turnover rates .

• Essential controls:

  • Empty vector controls

  • Wild-type DSS1(V) overexpression

  • Binding-deficient mutant DSS1(V) overexpression (e.g., equivalent to W39R)

  • Measurement of multiple known DSS1-dependent substrates (e.g., CDC6, C-MYC)

• Proteasome inhibition: Include proteasome inhibitors as controls to confirm the degradation pathway.

How can researchers effectively map the genomic distribution of DSS1(V) when antibody-based ChIP-seq proves challenging?

When standard ChIP-seq with DSS1(V) antibodies yields insufficient enrichment:

• CUT&Tag alternative: The Flag CUT&Tag approach successfully mapped DSS1 chromatin associations when ChIP-seq failed . Apply this method using:

  • Epitope-tagged DSS1(V) systems

  • The specific protocol outlined in section 2.3

• Controlled degradation system: Incorporate a dTAG-mediated degradation approach, comparing samples with and without dTAG treatment as a powerful specificity control .

• Comparative analysis: Correlation analysis between DSS1(V) occupancy and:

  • Other known interaction partners

  • Active chromatin markers at promoters and enhancers

  • Specific histone modifications

This approach successfully identified 54,757 DSS1-bound genomic regions and demonstrated that DSS1 genomic distribution aligns with INTAC subunits, with highest occupancy at promoters .

What is the recommended workflow for analyzing subcellular localization changes of DSS1(V) following DNA damage?

For analyzing DSS1(V) localization changes after DNA damage:

• Experimental design:

  • Treat cells with DNA damaging agents (e.g., ionizing radiation, hydroxyurea)

  • Fix cells at multiple time points (0, 1, 4, 8, 24 hours)

  • Process for immunofluorescence using the protocol in section 1.3

• Co-localization analysis:

  • Include co-staining for DNA damage markers (γH2AX)

  • Include RAD51 and BRCA2 as functional markers of homologous recombination repair

• Quantification approach:

  • Employ high-resolution confocal microscopy

  • Use ImageJ/Fiji for nuclear/cytoplasmic signal quantification

  • Apply correlation analysis to determine co-localization with repair factors

• Validation: Compare results between wildtype cells and cells expressing binding-deficient DSS1(V) mutants to establish functional significance of localization changes.

What quality control measures should be implemented when preparing DSS1(V) antibodies for sensitive applications like proximity ligation assays?

For proximity ligation assays (PLA) with DSS1(V) antibodies:

• Antibody validation criteria:

  • Confirm single band detection on western blots

  • Verify signal absence in knockout/knockdown cells

  • Test cross-reactivity with DSS1(I) using overexpression systems

• Pre-clearing protocol:

  • Pre-clear antibody solutions using cell lysates from DSS1(V) knockout cells

  • Filter through 0.22 μm membrane to remove aggregates

• PLA-specific controls:

  • Single antibody controls for each detection antibody

  • Competitive blocking with recombinant DSS1(V) protein

  • Omission of one primary antibody at a time

• Concentration optimization: Titrate antibody concentrations to determine the optimal signal-to-noise ratio specifically for PLA applications.

How can researchers overcome non-specific binding issues when using DSS1(V) antibodies in co-immunoprecipitation experiments?

To minimize non-specific binding in co-immunoprecipitation with DSS1(V) antibodies:

• Buffer optimization:

  • Include 0.1-0.5% NP-40 or Triton X-100 to reduce hydrophobic interactions

  • Test various salt concentrations (150-300 mM NaCl) to identify optimal stringency

  • Add 5% glycerol to stabilize protein complexes

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads before antibody addition

  • Use IgG from the same species as the DSS1(V) antibody for pre-clearing

• Bead selection:

  • Compare results between protein A, protein G, and protein A/G beads

  • Consider magnetic beads for cleaner isolation with less background

• Cross-validation approach:

  • Perform reciprocal co-IP using antibodies against known DSS1(V) interaction partners

  • Confirm interactions using alternative methods (e.g., proximity ligation assay)